Vaxart receives second 180-day Nasdaq extension to cure bid price deficiency until June 30, 2025

Vaxart, Inc.

Nasdaq notified Vaxart on Dec 31, 2024 of an additional 180-day compliance period to meet the $1.00 minimum bid price requirement.
Extension moves the cure deadline from Dec 30, 2024 to June 30, 2025.
Company is considering a reverse stock split as a potential cure for the deficiency.
If not compliant by June 30, 2025, Nasdaq will issue a delisting notice; Vaxart may appeal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.